Can Flash Glucose Monitoring (FlashGM) improve glucose management in Indigenous Australians with type 2 diabetes? A randomised controlled trial.

niversity of Melbourne0 个研究点目标入组 350 人开始时间: 2021年6月15日最近更新: 2024年7月29日

适应症

试验速览

暂无简介。

•1.Indigenous Australian
•2.Confirmed diagnosis of type 2 diabetes
•3.Age greater than or equal to 18 years and above
•4.HbA1c greater than or equal to 7.5% (58 mmol/mol) from either a recent blood test (within 4 weeks of screening date) or blood sample taken at screening determined through laboratory pathology testing. *must be laboratory confirmed HbA1c not point of care testing.
•5.Medicated with the same type of injectable therapies ± oral hypoglycaemic agents, for at least 6 weeks prior to screening:
•i.Insulin alone or with or without oral agents
•ii.GLP1 analogues (including subclasses) with or without oral agents
•iii.GLP1 analogues (including subclasses) and insulin with or without oral agents.

•1.Age < 18 years
•2.Type 1 diabetes mellitus
•3.Taking high doses of vitamin C supplements (more than 500 mg per day)
•4.Active malignancy requiring chemotherapy
•5.Known allergy to medical-grade adhesives
•6.On varying doses of corticosteroid therapy
•7.Using amphetamines, anabolic or weight-reducing therapies
•8.Pregnancy or actively planning pregnancy as HbA1c is not reliable during pregnancy and is the primary outcome.
•9.eGFR<15ml/min/1.732 or erythropoiesis stimulating agents or end-stage kidney disease
•10.Haemoglobinopathies
•11.Active illicit drug use or heavy alcohol use
•12.No informed consent

发起方

niversity of Melbourne